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Abstract
Shigellosis is the major global cause of dysentery. Shigella sonnei, which has historically
been more commonly isolated in developed countries, is undergoing an unprecedented ex-
pansion across industrializing regions in Asia, Latin America, and the Middle East. The pre-
cise reasons underpinning the epidemiological distribution of the various Shigella species
and this global surge in S. sonnei are unclear but may be due to three major environmental
pressures. First, natural passive immunization with the bacterium Plesiomonas shigelloides
is hypothesized to protect populations with poor water supplies against S. sonnei. Improving
the quality of drinking water supplies would, therefore, result in a reduction in P. shigelloides
exposure and a subsequent reduction in environmental immunization against S. sonnei.
Secondly, the ubiquitous amoeba species Acanthamoeba castellanii has been shown to
phagocytize S. sonnei efficiently and symbiotically, thus allowing the bacteria access to a
protected niche in which to withstand chlorination and other harsh environmental conditions
in temperate countries. Finally, S. sonnei has emerged from Europe and begun to spread
globally only relatively recently. A strong selective pressure from localized antimicrobial use
additionally appears to have had a dramatic impact on the evolution of the S. sonnei popula-
tion. We hypothesize that S. sonnei, which exhibits an exceptional ability to acquire antimi-
crobial resistance genes from commensal and pathogenic bacteria, has a competitive
advantage over S. flexneri, particularly in areas with poorly regulated antimicrobial use.
Continuing improvement in the quality of global drinking water supplies alongside the rapid
development of antimicrobial resistance predicts the burden and international distribution of
S. sonnei will only continue to grow. An effective vaccine against S. sonnei is overdue and
may become one of our only weapons against this increasingly dominant and problematic
gastrointestinal pathogen.
Introduction
Shigellosis, caused by members of the bacterial genus Shigella, is a severe and occasionally life-
threatening diarrheal infection. Worldwide, Shigella spp. are the most common cause of acute,
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bloody diarrhea (dysentery) and are responsible for a significant proportion of the burden of
morbidity and mortality associated with diarrheal disease [1,2]. In Asia alone, it is estimated
that there are 125 million infections and 14,000 deaths due to shigellosis annually [3]. As a re-
sult of the considerable global burden, low infectious dose [4], clinical severity, and frequent re-
ports of emerging antimicrobial resistance against first- and, more recently, second-line
therapies [5,6], a vaccine against Shigella infections is a growing necessity. Yet, more than a
century after the discovery of the agent of bacillary dysentery, there is still neither a licensed
vaccine nor agreement on the precise mechanisms that induce Shigella immunity [7]. Vaccine
development is further complicated by the probable need for a multivalent combination of O
polysaccharide antigens to protect against a variety of heterogeneously distributed serotypes
[8].
The genus Shigella incorporates four species. Shigella dysenteriae was historically responsi-
ble for large epidemics [9] yet is now rarely identified [8]. Similarly, S. boydii is also infrequent-
ly isolated. S. flexneri, however, is common globally and traditionally isolated most frequently
in resource-poor countries [10]. S. flexneri has 15 different serotypes distributed heteroge-
neously across different regions, with predominant serotypes including S. flexneri 2a, 3a, and 6
[8,11]. Finally, S. sonnei is also prevalent globally, although traditionally most commonly de-
tected in high-income regions [10,12]. S. sonnei has only one serotype.
S. sonnei: An Emergent Pathogen
Reasons behind the conventional dominance of S. sonnei in industrialized countries remain
unclear [13]. However, an increasing proportion of shigellosis due to S. sonnei generally corre-
lates with improving economic prosperity [12], which in the context of many rapidly develop-
ing countries, has led to a proportional decrease in S. flexneri and the simultaneous emergence
of S. sonnei [14]. This shift toward S. sonnei has been documented in many regions in Asia,
Latin America, and the Middle East (Fig 1) [15–20], with proven explanations behind such an
epidemiological phenomenon lacking. This review aims to summarize the existing evidence as
to why S. sonneimay predominate in high-income countries and why it is now emerging in re-
gions traditionally dominated by S. flexneri and explores the implications of the growing threat
of this increasingly antimicrobial-resistant pathogen for public health globally.
Plesiomonas shigelloides: Passive Environmental Immunization?
One of the principal theories regarding the lack of S. sonnei in industrializing areas focuses on
the Gram-negative bacteria P. shigelloides, which like Shigella falls within the large eubacterial
family of the Enterobacteriaece. P. shigelloides and S. sonnei share an identical lipopolysaccha-
ride (LPS) O-side chain (confirmed by nuclear magnetic resonance [NMR] and mass spec-
trometry) that is thought to be the major surface antigen targeted by the adaptive immune
system during Shigella infection [21,22]. These surface antigens are cross-reactive, and vaccines
prepared from O-antigen derived from P. shigelloides have been shown to be reasonably effec-
tive in preventing infection with S. sonnei in humans [23,24]. The O-antigen gene cluster is lo-
cated on the S. sonnei invasion plasmid and is essential for penetration of host epithelial cells
[25]. Evidence suggests not only that S. sonnei acquired the O-antigen gene cluster from P. shi-
gelloides but also that this acquisition was the defining event in the emergence of S. sonnei [26].
Due to the cross-reactive nature of the S. sonnei/P. shigelloides O-antigens, Sack and col-
leagues suggested that exposure to P. shigelloides serotype O17 leads to protection against infec-
tion with S. sonnei [27]. In areas with poor-quality water supplies, the authors postulated that
exposure to P. shigelloides occurs frequently and thus disease due to S. sonnei is rare, as the
population is effectively naturally immunized [27]. Although P. shigelloides is found in water
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and environmental samples in both industrialized and industrializing countries [28,29], water
treatment practices are likely to prevent frequent exposure in regions with adequate sanitation.
Highlighting this, outbreaks of diarrheal disease thought to be due to P. shigelloides occurred
after a lapse in water chlorination in Japan in the mid-1970s [30]. Although the serotypic distri-
bution of P. shigelloides has not been well described [31], serotype O17 has been reported in
both water and stool samples from patients admitted for diarrhea in industrializing regions
[32,33], lending credence to the hypothesis of water-driven immunization at the population
level.
The phenomenon of passive immunization in low-income countries would explain, at least
in part, why S. sonnei is proportionally more commonly isolated in industrialized countries.
Accordingly, an increase in the proportion of Shigella episodes due to S. sonnei would occur
concurrently with economic development and improved water supplies [27]. Ram and col-
leagues confirmed this economic trend by identifying a strong positive correlation between
country-level GDP and proportion of isolated Shigella due to S. sonnei from 56 studies con-
ducted from 1984–2005 (R = 0.55, p< 0.0001) [12]. Therefore, the combination of improving
economic outlook and fulfillment of the Millennium Development Goals (MDGs) will lead to
an improvement of drinking water supply, a drop in population-level cross protection against
S. sonnei, and potentially to a global increase in S. sonnei infections in heavily populated re-
gions currently undergoing such transitions [34].
Acanthamoeba: An Environmental Host?
Acanthamoeba is the most common amoeba found globally, with a wide distribution in both
aquatic and nonaquatic environments [35]. Amoeba such as Acanthamoeba are known to act
as environmental hosts for a variety of intracellular pathogens including Helicobacter pylori,
Fig 1. The ratio of S. sonnei to S. flexneri isolated from 100 countries, 1990–2014. The darker the color, the higher the proportion of S. sonnei isolated
from each country; the lighter the color, proportionally higher the proportion of S. flexneri isolated. Countries colored grey indicate no data on species were
identified. To generate this map, we performed an extensive literature review in PubMed using the term “Shigella” followed by the name of 178 countries. The
most recent publication that included species information that was nonoutbreak and nontravel associated was included as representative of each country. If
country data were pre-1990 or were not available on PubMed, the Gideon Infectious Disease encyclopedia as well as national reference laboratory data were
referenced where possible. References are listed by country in the supplementary material (S1 Table).
doi:10.1371/journal.pntd.0003708.g001
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Vibrio cholerae, and also various Shigella spp. [36–38]. The uptake of bacteria into amoebic
cysts allows the bacteria to persist in adverse environmental conditions, including desiccation,
starvation, and a variety of chemical and physical agents [39]. Acanthamoeba cysts, which
form when triggered by nutritional or osmotic stress, are particularly resistant to chlorine treat-
ment [40]. Found commonly through environmental sampling [41], Acanthamoeba has been
identified in public water supplies in developed countries with appropriate chlorination levels
[42] and in hospital water supplies [43] and can also be isolated from drinking water supplies
in industrializing regions [44].
Recent evidence confirms that S. sonnei, S. dysenteriae, and S. flexneri can be taken up by
the species Acanthamoeba castellanii when grown under laboratory conditions [36,45,46].
Once phagocytized, Shigella spp. are localized in A. castellanii vacuoles and eventually in the
cysts [36,45] and can survive for over three weeks [45]. Notable differences in symbiotic growth
were recorded with respect to amoebic uptake between Shigella species. S. sonnei has been
shown to be efficiently taken up and maintained by A. castellanii at temperatures between 18–
30°C [36,46]; indeed, growth of S. sonnei in the presence of Acanthamoeba was found to exceed
that of S. sonnei cultured alone [46]. S. flexneri, however, was found to significantly inhibit A.
castellanii growth in the laboratory at 30°C [46]. Inhibition and killing of A. castellanii by S.
flexneri is due to activation of invasion genes, which may induce apoptosis through the secre-
tion of effector proteins into the host cell via the type three secretion system [47,48].
The growth and survival rates of Shigella in the cytoplasm of the amoeba resemble their pat-
tern of growth and survival in mammalian macrophages [45,49]. In fact, it has been suggested
that growth in the amoebic intracellular niche may have influenced the ability of Shigella to
survive in the mammalian phagocytic cell environment [50]. Additionally, as free-living amoe-
ba feed on bacteria, fungi, and algae, lateral gene transfer within the amoeba phagolysosome
may have facilitated genetic adaptations that allow for the expression of pathogenic or symbiot-
ic phenotypes based on impact on the host cell [51,52]. It has been further suggested that amoe-
bae themselves represent an important genetic reservoir for internalized microbes [51]. For
example, there has been an observed increase in resistance to various antimicrobials and bio-
cides in Legionella pneumophila grown within free-living amoeba [53], which may be due to se-
lection within the amoeba itself [51].
All aspects considered, available evidence suggests that A. castellaniimay contribute to
transmission of S. sonnei in temperate regions by phagocytizing S. sonnei, thus allowing the
bacteria to circumvent the effects of chlorination and good sanitation [54]. As S. flexneri has
been shown to inhibit growth of A. castellani [46], the amoeba may not be a viable reservoir for
S. flexneri in either developed or industrializing countries. Protozoa appear to play an impor-
tant role in the transition of bacteria from the environment to mammals and as such may be
the source of emerging pathogenic bacteria [50], and may play an increasing role in the epide-
miology of S. sonnei in industrializing regions as the prevalence increases.
Antimicrobial Resistance: A New Defense Strategy?
Phylogeographical analyses of a large number of S. sonnei isolates spanning several continents
and several decades in a publication by Holt et al. demonstrated that all contemporary S. sonnei
infections are due to a small number of clones that dispersed globally from Europe within the
last 500 years [34]. Four distinct lineages of S. sonnei were identified, with lineage III the most
prevalent globally, becoming dominant in Asia, Africa, and South America [34]. S. sonnei be-
longing to lineage III are characterized by the presence of distinct class II integron (In2), which
confers resistance to trimethoprim, streptothricin, and streptomycin [55]. Many lineage III iso-
lates were also found to harbor a genetic locus on a small plasmid conferring resistance to a
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variety of additional antimicrobials including tetracycline and sulphonamides. Holt and col-
leagues indicated that In2 was likely acquired during the mid-20th century, after which the
clone spread internationally, undergoing contemporary global dispersal and localized clonal
expansions [34].
This localized microevolution of S. sonnei appears to be largely driven by selection pressure
induced by antimicrobials [56]. The determinants for antimicrobial resistance in Shigella are
generally located on mobile genetic elements such as plasmids, transposons, and integrons
[55]. Horizontal gene transfer (HGT) of such elements is now recognized to be an important
driver of bacterial evolution [57,58]. One study, for example, estimated 18% of the 4,288 genes
of Escherichia coli strain MG1655 were acquired laterally since the species diverged from the
Salmonella lineage 100 million years (Myr) ago, a rate of 16 kb/Myr/lineage [59]. Transfer of
mobile genetic elements between members of the Enterobacteriaceae is known to be responsi-
ble for the dissemination of antimicrobial resistance genes and the emergence of a variety of
multidrug-resistant (MDR) Gram-negative bacteria globally [55,60,61].
S. sonnei can acquire advantageous chromosomal and plasmid-mediated resistance genes
through HGT from both commensal and pathogenic bacteria circulating locally, enhancing its
ability to establish infection, prolonging shedding, and, presumably, outcompeting antimicro-
bial-susceptible bacteria [56]. A study of>250 S. sonnei isolates collected over 15 years in Viet-
nam documented the rapid emergence and dominance of successful clones of S. sonnei after
the acquisition and fixation of plasmids conferring colicin production/immunity and resistance
to third-generation cephalosporins in two separate genetic bottleneck events [56]. In areas with
unregulated antimicrobial use, S. sonneimay have abundant opportunity to acquire locally de-
rived resistance genes [62]. In countries with restricted antimicrobial usage, for example, S. son-
nei are generally more susceptible to quinolones [5], presumably because of lower selective
pressure combined with reduced availability of resistance genes in the circulating accessory
gene pool. Such a phenomenon is thought to be leading to increasingly successful clones in
areas of unregulated antimicrobial use and could lead to a rapidly growing and increasingly
challenging public health problem in many industrializing areas [56].
In 2005, the WHO published guidelines recommending ciprofloxacin to be used as the first-
line treatment for dysentery [63]. The late 2000s saw the first documented resistance in S. son-
nei against fluoroquinolones [5]. Phylogeographical data from Holt and colleagues indicate
marked differences in the global prevalence of gyrA (DNA gyrase) mutations, which confer re-
sistance to quinolones and reduced susceptibility to fluoroquinolones. Strong selection for
quinolone resistance was identified, as the facilitating mutations have occurred independently
on multiple occasions in several different lineages and genetic locations [34]. Unless the use of
fluoroquinolones becomes regulated in areas of current unrestricted use, ciprofloxacin will like-
ly become ineffective for treating Shigella infections in the near future [5]. Yet pivmecillinam,
ceftriaxone, or azithromycin may be effective alternatives [64,65], depending on local resis-
tance patterns.
Does Shigella sonnei Have a Competitive Advantage?
Taken together, evidence suggests that the global burden of S. sonneimay be growing com-
pared to that of S. flexneri. This phenomenon may not only be due to the global improvements
in water quality and an ability of S. sonnei to grow successfully within Acanthamoeba but may
also be due to a potential, but as yet unproven, ability to acquire and/or maintain a wider array
of antimicrobial resistance genes. Indeed, it has been speculated that the plasmid composition
and resistance profiles may differ between the Shigella species isolated from contemporaneous
patient populations in the same locations (Fig 2) [15,66–71]. Although S. sonnei can acquire
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003708 June 11, 2015 5 / 13
extended-spectrum beta-lactamase (ESBL)-mediated resistance from other Enterobacteriaceae,
particularly E. coli and Klebsiella spp. [72], it is not currently known whether S. flexneri and S.
sonnei acquire resistance genes from each other. Toro et al. suggested that there is a greater re-
striction barrier for conjugal plasmids between S. sonnei and S. flexneri than between other
Gram-negative donors and recipients [67]. A differential ability to acquire and/or maintain
plasmids between S. flexneri and S. sonnei from other bacterial donors may also explain dis-
crepant resistance profiles between contemporaneous species, although such a phenomenon
has yet to be explicitly investigated.
Levels of inflammation in the gut during infection could explain differences in the ability to
acquire mobile genetic elements of resistance between the species. Stecher et al. demonstrated
that inflammatory responses in the gut during infection may facilitate conjugative transfer and
reassortment of plasmid-encoding genes between pathogens and commensal organisms [73].
Although it was shown recently that S. flexneri is able to modify its LPS structure to dampen
the inflammatory innate immune response to allow it to successfully evade detection in the
Fig 2. Antimicrobial resistance and presence of resistance-conferring genes in S. sonnei and S. flexneri. Plots on the left show proportion of
antimicrobial resistance determined by minimum inhibitory concentration (MIC) amongst isolates collected from Vietnam over a 15-year period (n = 231 for S.
sonnei and 136 for S. flexneri) [34,56]. S. sonnei are shown by darker colors on the top of each graph, and S. flexneri is shown by lighter colors at the bottom.
Plots on the right show the proportion of S. sonnei (dark color, top of each graph) and S. flexneri (light color, bottom of each graph) found to have varying
resistance genes present on either plasmids or the chromosome. See Supporting Information (SI) S1 Text for a description of procedures. The color of the
gene corresponds with the color of the antimicrobial to which it confers resistance on the left. AMP: ampicillin; CHL: chloramphenicol; CIP: ciprofloxacin;
CRO: ceftriaxone; GAT: gatifloxacin; GEN: gentamicin; NAL: nalidixic acid; OFX: ofloxacin; SXT: cotrimoxazole; TET: tetracycline; TMP: trimethoprim.
doi:10.1371/journal.pntd.0003708.g002
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initial phases of infection [74], it is not yet known whether this occurs during S. sonnei infec-
tion. Investigations into differential inflammatory response between the Shigella species during
infection and their relationship to HGT within the human gastrointestinal tract are warranted.
Finally, S. sonnei has been shown to be genetically more similar to its ancestor E. coli than to
other Shigella species [75,76]. Gene retention from E. coli potentially imbues S. sonnei with a
higher likelihood for survival in the environment or an environmental adaptive host [75], such
as Acanthamoeba. S. flexneri, however, loses genes faster than any other Shigella species and is
the most genetically distant of the Shigellae from E. coli [76]. Hershberg and colleagues suggest
a potential “point of no return” for Shigella in that once it undergoes enough purifying selec-
tion, it cannot regain enough of its lost functionality to escape niche limitation [76]. Does en-
hanced capacity for genomic plasticity explain the hypothesized increased ability of S. sonnei to
acquire or maintain plasmids from other bacterial donors [77]? Experimental evidence of dif-
ferences in gene acquisition and retention between the two species is needed.
Next Steps
We predict that the combination of improving water supplies and rapid acquisition and main-
tenance of mobile elements conferring advantageous resistance genes is accelerating a Shigella
species shift toward S. sonnei dominance, which traditionally has been shown to occur over a
period of decades in individual countries (Table 1, S1 Table) [78,79]. To counter this rapid spe-
cies replacement, many questions regarding the epidemiology of S. sonnei and, crucially, vac-
cine development need to be addressed. Identifying prominent transmission routes of S. sonnei
and S. flexneri in resource-poor countries should remain a primary goal. Indeed, experiments
to determine the relative fitness of each species in varying environmental conditions and inves-
tigating antimicrobial fitness [80] would provide information on potential niche preferences
and add insight into which accessory gene pools each species samples from. Finally, longitudi-
nal monitoring of water supplies for the presence of both P. shigelloides and A. castellanii
would help to verify the hypotheses presented in this review in regard to both a reduction of
population immunity against the S. sonnei O-antigen as well as an environmental amoeba
niche for these bacteria.
Furthermore, research on the genetic structure of global S. flexneri populations is warranted
in order to help further understand the global species shift and to explore the global and
Table 1. Summary of factors behind the traditional and current epidemiological distribution of S. sonnei and S. flexneri.
Factor Region
Industrializing Industrialized
Explanation of traditional
geographical distribution
1. S. sonnei is not present because of population immunity
due to cross protection from exposure to P. shigelloides
found in contaminated water supplies [26]
1. S. sonnei is present because of a lack of cross
protection from exposure to P. shigelloides due to
clean water supplies
2. S. ﬂexneri is not able to grow within the common amoeba A.
castellanii [46]
2. S. sonnei is symbiotically phagocytosed by A.
castellanii and can withstand chlorination and other
harsh environmental conditions [36]
Why is the burden of S.
sonnei growing?
1. Improving water supplies may lead to a decrease in the
prevalence of P. shigelloides, resulting in lack of cross
protection against S. sonnei [27]
2. Expansion of S. sonnei from Europe in the last 500 years
and subsequent microevolution due largely to local
antimicrobial use [34,56]
3. Proposed competitive advantage of S. sonnei against S.
ﬂexneri due to an enhanced ability to acquire and maintain
mobile resistance genes from other bacterial species
doi:10.1371/journal.pntd.0003708.t001
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localized microevolution of this pathogen over time. Such analyses would help to predict the
role of S. flexneri in the context of improving sanitation and growing prevalence of S. sonnei
worldwide. Finally, although plagued with many setbacks [11], the development of a sufficient-
ly safe and effective S. sonnei vaccine may be feasible in the coming decade. However, in order
to carry out properly designed vaccine trials in the future, outstanding questions regarding cor-
relates of immunity, incidence in the community, seroconversion rates, and the role of mater-
nal antibody in the first years of life will need to be answered.
In conclusion, S. sonnei represents an emerging threat to public health globally. With con-
tinuing efforts for improvements in water and sanitation worldwide, population-level immuni-
zation against S. sonnei due to exposure to P. shigelloides is declining. Additionally,
environmental hosts such as A. castellani represent an important yet potentially overlooked
reservoir of S. sonnei and may explain in part the persistence of S. sonnei in regions with a rea-
sonably good standard of sanitation. Finally, the incredible ability of S. sonnei to acquire resis-
tance to a variety of widely used antimicrobials may endow the pathogen with a competitive
advantage over sensitive bacterial competitors and predicts its emergence in areas with unregu-
lated antimicrobial use. Combined, this evidence suggests alarming increases in global preva-
lence of S. sonnei and unprecedented levels of resistance, demanding a vaccine in the near
future that can be administered to the most vulnerable populations, particularly young children
in rapidly industrializing countries.
Boxes
Box 1. Key Learning Points
1. Traditionally, the various species of the bacterial genus Shigella have a distinct geo-
graphical distribution. S. sonnei is most commonly isolated in industrialized coun-
tries, whereas S. flexneri is more commonly isolated in industrializing regions.
However, S. sonnei is now becoming recognized as a common enteric pathogen in
many industrializing regions. The exact mechanisms catalyzing this shift in the epide-
miological distribution are unclear.
2. Improving the quality of drinking water supplies in industrializing regions is likely to
reduce cross protection against S. sonnei derived from the bacterium P. shigelloides,
which is commonly found in contaminated water.
3. S. sonneimay be efficiently phagocytized by the ubiquitous amoeba species A. castel-
lani, thereby providing it with a reservoir in which to withstand chlorination and
other harsh environmental conditions.
4. In comparison to S. flexneri, S. sonnei has a greater ability to develop resistance to
broad-spectrum antimicrobials. We suggest that S. sonnei is more likely to accept and
maintain horizontally transferred DNA, which gives it a competitive advantage
against S. flexneri, particularly in areas with unregulated antimicrobial use.
5. With ongoing improvements in the international quality of water supplies and rapid
development of antimicrobial resistance, the burden of S. sonnei is likely to grow sub-
stantially. A vaccine against S. sonnei is increasingly necessary.
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Supporting Information
S1 Table. Country-specific references for Fig 1 showing the ratio of S. sonnei to S. flexneri
isolated from 100 countries, 1990–2014.
(DOCX)
S1 Text. Methods for antimicrobial resistance and gene content data shown in Fig 2. Data
are derived from analyses of 367 Shigella isolates collected between 1995 and 2010 from Viet-
nam (136 S. flexneri and 231 S. sonnei). Resistance was determined by MIC and gene content
analysis from Illumina genome sequencing data.
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